iShares Global Healthcare ETF IXJ
112.43 USD -0.54 (-0.48%)
Nov 6, 2026, 9:59 AM EST
112.12 Day range 112.62
90.28 52-week range 116.89
- YTD
- +15.43%
- 1 year
- +22.38%
- Market cap
- 4.64B
- EPS (ttm)
- 4.14
- P/E ratio
- 27.17
- YTD return
- +15.43%
- 1-year return
- +22.38%
- Volume
- 29.22K
- Avg volume
- 227.57K
- Open
- 112.12
- Previous close
- 112.97
- Day's range
- 112.12 – 112.62
- 52-week range
- 90.28 – 116.89
6M +18.64 (+20.26%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 105.03
- 200-day average
- 99.08
Next earnings
Consensus EPS estimate 0.00.
About iShares Global Healthcare ETF
The fund seeks to track the investment results of the S&P Global 1200 Health Care (Sector) Capped IndexTM (the “underlying index”), which measures the performance of companies that S&P Dow Jones Indices LLC (the “index provider” or “SPDJI”), a subsidiary of S&P Global, Inc., deems to be a part of the healthcare sector of the economy and that SPDJI believes are important to global markets. The underlying index is a subset of the S&P Global 1200, which is designed to measure the performance of large-capitalization stocks from major global markets, as determined by SPDJI.
News
City of London Investment Management Co. Ltd. Acquires New Shares in iShares Global Healthcare ETF $IXJ
iShares Global Healthcare ETF $IXJ Shares Newly Acquired by Everett Harris & Co. CA
From Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave
White House Reportedly Preparing To Oust FDA Commissioner Marty Makary
Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules
Trump Admin Targets Medicaid Spending On Immigrants, Threatening Over $12 Billion California Program
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
World Health Organization Responds to Trump's Order, Reminds Decades of Successful Health Achievements Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Why WHO Did Not Recommend Convalescent Plasma Therapy For COVID-19
Your note
Sign in to keep a note on IXJ — it syncs with the Stock Master app.
